Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses the Next Steps for Ipilimumab
Axel Hoos, MD, PhD
Advertisement
Articles by Axel Hoos, MD, PhD
Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses Which Patients are Eligible to Receive Ipilimumab
Dr. Axel Hoos medical lead at bristol-myers squibb on the Ipilimumab Plus Dacarbazine Combination Trial
Dr. Axel Hoos medical lead at Bristol-Myers Squibb on Why Melanoma is Amenable to Immunotherapy
Dr. Axel Hoos from Bristol-Myers Squibb Explains the Future of Immunotherapy and Ipilimumab's role
Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies
Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success
Dr. Axel Hoos the medical lead in Immunology/Oncology at Bristol-Myers Squibb Discusses the Clinical Kinetics of Immunotherapy
Dr. Axel Hoos Medical Lead in Immunology/Oncology at Bristol-Myers Squibb on a Possible Successor Drug to Ipilimumab
Dr. Hoos From Bristol-Myers Squibb Discusses Key Points of the Ipilimumab Trial
Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab
Advertisement
Latest Updated Articles
Dr. Hoos Discusses Key Points of the Ipilimumab TrialPublished: June 15th 2011 | Updated:
Dr. Hoos on a Possible Successor Drug to IpilimumabPublished: June 22nd 2011 | Updated:
Dr. Hoos Discusses the Next Steps for IpilimumabPublished: August 9th 2011 | Updated:
Dr. Hoos Discusses the Clinical Kinetics of ImmunotherapyPublished: July 1st 2011 | Updated:
Dr. Hoos on Tools Available to Measure Ipilimumab's SuccessPublished: July 7th 2011 | Updated:
Dr. Hoos Describes Ipilimumab and Future ImmunotherapiesPublished: July 13th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5